Vaccinogen Engages D. Barry Boyd, M.D., M.S., as Senior Oncology Advisor

Veteran Medical Oncologist Joins Vaccinogen's Medical Advisory Board to Advance its Promising Immunotherapies

Oct 28, 2015

BALTIMORE, Oct. 28, 2015 /PRNewswire/ -- Vaccinogen, Inc. (OTC.QB: VGEN), a cancer immunotherapy development company, today announced the engagement of D. Barry Boyd, M.D., M.S., to the newly established position of Senior Oncology Advisor and his appointment to the Company's Medical Advisory Board. Dr. Boyd is a specialist in the treatment of cancer and will provide expert counsel to Vaccinogen as the company pursues its ACTIVE Phase IIIb OncoVAX® clinical trial and expands its human antibody program (HuMabs).

Andrew L. Tussing, Chairman and Chief Executive Officer of Vaccinogen, stated, "Dr. Boyd's extensive experience in oncology will make him an invaluable member of the Vaccinogen team as we continue to demonstrate the significant value potential of our OncoVAX® and HuMabs programs. We are excited about several upcoming clinical and operational milestones, and we believe Dr. Boyd is the perfect advisor to help ensure we meet our objectives successfully and efficiently."

Dr. Boyd has 23 years of experience as a board-certified medical oncologist/hematologist and is a specialist in cancer treatment and recovery. He is an attending physician at Greenwich Hospital – Yale Medical Center. He is also Assistant Clinical Professor and a lecturer in the Cancer Module in the second year on Cancer Nutrition at the Yale University School of Medicine. In 2010, Dr. Boyd was appointed Director of Cancer Nutrition for the Yale Health System and is developing a Center for Cancer Nutrition Education in affiliation with the Yale Smilow Cancer Survivorship Program. Dr. Boyd is the founding president of The Integrative Cancer Care Research Foundation and a board member of Environment and Human Health, Inc., a nonprofit organization made up of physicians and public health professionals dedicated to the purpose of protecting public health from environmental harms. In 2005, Dr. Boyd published a book titled, The Cancer Recovery Plan.  Dr. Boyd received an M.S. in nutritional biochemistry from the Institute of Human Nutrition, Columbia University, and an M.D. from Cornell University Medical College.

Dr. Boyd added, "I'm pleased to join Vaccinogen because I believe the Company has multiple opportunities to improve patient outcomes, based on its novel cancer vaccine technology and exciting HuMabs program. Each of these novel approaches involves deriving a powerful anti-cancer therapy from natural human immunity, and in the case of OncoVAX®, leveraging a patient's own tumor cells to create a protective vaccine designed to prevent cancer recurrence.  I look forward to working closely with Andy and his senior scientific and business development team to advance these new immunotherapies toward commercialization and into the hands of physicians."

About Vaccinogen, Inc.

Vaccinogen, Inc. is a cancer vaccine company planning to clinically test OncoVAX®, a treatment designed to prevent the recurrence of stage II colon cancer and potentially other solid tumors. It is a patented process that leverages a patient's own live tumor cells to launch a broad immune response against minimal residual disease. Vaccinogen believes that OncoVAX®, at an optimal dose and regimen, is the first colon cancer vaccine to demonstrate effectiveness in preventing cancer recurrence after surgical resection by addressing the diversity of cancer cells inherent to each patient's tumor. Five clinical studies of OncoVAX®, including a statistically significant phase III trial with the optimum dose and regimen, have been completed. Vaccinogen expects to begin enrolling patients in a pivotal phase IIIb trial under a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) once adequate funding is obtained. Vaccinogen has also secured an option agreement to acquire a high-throughput, single-cell screening and analysis system known as DiCAST, which the company expects to use to screen patient-derived biological samples in order to accelerate its human monoclonal antibody (HuMab) program for the development of next-generation cancer vaccines and immunotherapies. More information is available at

Forward Looking Statement
Some of the statements contained in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipates", "believe", "plan", "intend", "expect", "likely", "may", "should", "will" and similar references to future periods. Vaccinogen has based these forward-looking statements largely on its expectations and projections about future events and trends affecting the financial condition and/or operating results of our business. Forward-looking statements involve risks and uncertainties; particularly those risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and the risks associate with the company's continuing efforts to obtain adequate funding to pursue its goals.  In addition, these forward-looking statements involve risks and uncertainties outlined in our most recent periodic reports filed with the Securities and Exchange Commission. There are important factors that could cause actual results to be substantially different from the results expressed or implied by these forward-looking statements. Therefore, you should not rely on these forward-looking statements. Vaccinogen does not undertake any obligation to update this forward-looking information.

SOURCE Vaccinogen, Inc.

For further information: Media / Investor Contacts: Jason Rando /Joshua Drumm, Ph.D., Tiberend Strategic Advisors, Inc., 212-375-2665 / 2664,,

print email rss